There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
Purity by HPLC
Not less than 95 %
Hazard Compound
Refer MSDS for accurate information.
Overview
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
![N,N-Bis(trimethylsilyl)-(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutylamine](https://structures.clearsynth.com/CS-O-37985.png)